Replimune's SWOT analysis: oncolytic immunotherapy stock faces pivotal year
Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment, ...
Replimune Group (NASDAQ:REPL) Price Target Raised to $27.00
Replimune Group (NASDAQ:REPL – Get Free Report) had its price target raised by investment analysts at BMO Capital Markets ...
PharmiWeb3h
Chiesi Group appoints three new independent Non-Executive Directors to its Board, supporting company evolution and growth
Chiesi, the international research-focused biopharmaceutical Group, announces the appointment of three new independent Non-Executive Directors (NEDs) to its Board: Roch Doliveux, Paolo Pucci and ...
Replimune Group’s Promising Outlook: FDA Priority Review and Positive Trial Data Support Buy Rating
Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on REPL stock, giving a Buy rating yesterday.Invest with ...
Yahoo Finance6d
Replimune price target raised to $21 from $17 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares. The firm expects a “relatively uneventful” FDA ...
Investing6d
Replimune's SWOT analysis: oncolytic immunotherapy stock faces pivotal year
Replimune Group Inc is focused on developing novel oncolytic immunotherapies for the treatment of various cancers. The company's lead product candidate, RP1, is being developed for the treatment ...
Investing6d
Replimune's SWOT analysis: oncolytic immunotherapy stock faces pivotal year
Replimune Group Inc is focused on developing novel oncolytic immunotherapies for the treatment of various cancers. The company's lead product candidate, RP1, is being developed for the treatment of ...
news.stocktradersdaily1d
(REPL) Trading Advice
Trading Advice for Replimune Group Inc. REPL including day trading swing trading and long term investing plans for REPL ...